SLIDE 1
OHSU
Research at OHSU (Fiscal Year 2013):
- $340.3 Million in Research Expenditures
- $220.9M from NIH
- $ 42.5M from industry
- $ 41.5M from other US Federal Agencies
- $ 34.2M from private organizations
- $ 1.2M from nonfederal government
Global 1000 Conference University Startup Portfolio Andrew R.O. - - PowerPoint PPT Presentation
Global 1000 Conference University Startup Portfolio Andrew R.O. - - PowerPoint PPT Presentation
Global 1000 Conference University Startup Portfolio Andrew R.O. Watson, PhD, CLP March 19, 2014 OHSU Research at OHSU (Fiscal Year 2013): $340.3 Million in Research Expenditures $220.9M from NIH $ 42.5M from industry $
SLIDE 2
SLIDE 3
Research Strengths at OHSU
- Vaccine development
- Therapeutic approaches against serious infectious diseases
- Magnetic resonance techniques and technologies
- Non-human primate models
- Neuroscience
- Rare diseases
- Spatial Systems Biomedicine – molecular medicine in four
dimensions
- Cardiovascular
- Cancer
- The $1B Knight Cancer Challenge
SLIDE 4
Commercialization at OHSU
BioTech MedTech Other
10 20 30 40 50
Cumulative # Startups since 1998
FY98-FY09 FY10 FY11 FY12 FY13
SLIDE 5
Developing safer anti-thrombotics without the side effects of all currently marketed treatments Three products in development: stand-alone emergency use, use when bleeding risk is moderate, and in conditions that are intrinsically accompanied with bleeding Aronora is the recipient of multiple awards from the NIH as well as a participant in Bayer’s Grants4Targets initiative Operations in Portland, OR and Bayer’s CoLaborator in San Francisco, CA Aronora seeks private investment, strategic partnerships, and out-licensing
- pportunities that are consistent with their business strategy
www.aronorabio.com
SLIDE 6
Developing a new class of molecules known as Recombinant T cell receptor Ligands (RTLs) to treat autoimmune inflammatory diseases Lead compound, which has received Orphan Drug status from the US FDA, is entering Phase II clinical trials for Multiple Sclerosis funded by the US Department of Veterans Affairs Operations in Tigard, OR and San Mateo, CA Next goal after phase II: a partnership with a pharmaceutical company to help bring the lead product to market
www.artielle.com
SLIDE 7
Developing a novel class of biopharmaceutical and diagnostic test solutions for the cardiovascular disease industry GammaCoeurTM – Measurable cardiovascular disease Dx assay for prognosis and preventative care GammaSealTM – High strength, natural surgical sealant for large artery vascular surgery or wound repair GammarinTM – Non-immunogenic, short acting anti-coagulant blood thinner for post- surgical venous thromboembolism control Operations in Portland, OR Seeking $1.5M Series A Round focused on GammaCoeur development www.gamma-therapeutics.com
SLIDE 8
The internet’s first library of real patient video case studies, viewable on any web-enabled device - including tablets and smartphones. Current libraries include Pediatrics cases and Emergency Medicine cases – libraries launched in 2013 The founders are both proven pioneers in the fields of video diagnosis and
- nline education. One, a clinician, has perfected the method of capturing
relevant clinical video content. The other has been at the forefront of two important online trends – health information and online learning. Operations in Portland, OR Next: Creation and growth of additional libraries, subscribership and new products
www.reeldx.com
SLIDE 9